Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Administration of CBG000592 (riboflavin/vitamin B2) in patients with acute ischemic stroke to know if it causes a reduction of glutamate-mediated excitotoxicity.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Castillo, José, M.D.
• Treatments: Riboflavin; Vitamin B Complex; Vitamins

Criteria

Inclusion Criteria:

1. Patients older than 18 years, both men and women.

2. Patient or legal representative able to understand and sign the informed consent.

3. Patients with suspected stroke within 3 hours of onset.

Exclusion Criteria:

1. Women of childbearing age, with potential for pregnancy or breastfeeding.

2. Patients with a score ≥ 2 point 1a in the NIHSS scale.

3. Scale pre-stroke modified Rankin ≥ 2.

4. Inability to prior testing image needed for the study.

5. Previous disorders that may interfere with the interpretation of neurological scales.

6. Treatment with probenecid, tricyclic antidepressants, phenothiazines, streptomycin, erythromycin, tyrothricin, tetracyclines and carbomycin, at the time of inclusion.